Literature DB >> 7796985

Peptide-based radioimmunoassay for the two isoforms of the human insulin receptor.

G Sesti1, R D'Alfonso, M D Vargas Punti, L Frittitta, V Trischitta, Y Y Liu, P Borboni, R Longhi, A Montemurro, R Lauro.   

Abstract

The insulin receptor exists in two isoforms differing by the absence (HIR-A) or presence (HIR-B) of 12 amino acids in the COOH-terminus of the alpha-subunit as a consequence of alternative splicing of exon 11. In this study, we developed a radioimmunoassay for the two isoforms employing antibodies raised against two peptides, one (Pep-12) corresponding to residues encoded by exon 11, and the other (Pep-13) corresponding to a COOH-terminal domain of the alpha-subunit which is common to both HIR-A and HIR-B isoforms. These peptides were iodinated and used as both ligands and standards. The assay is specific, highly reproducible, and sensitive with a detection limit of 10 fmol of receptor. One mole of purified insulin receptor, measured by Scatchard analysis, is read as one mole of receptor in the radioimmunoassay with either Pep-12 or Pep-13 as standards. The radioimmunoassay is applicable to the measurement of total content and relative abundance of the two isoforms in extracts from various tissues. We applied the radioimmunoassay to measure the relative abundance of the two isoforms in fat and muscle from normal, obese non-diabetic and non-insulin-dependent diabetic (NIDDM) subjects. Results demonstrate that expression of the low-affinity HIR-B form is significantly increased in obese and NIDDM subjects compared with control subjects. In addition, the increased expression of the HIR-B isoform was significantly correlated with both body mass index (r = 0.52; p = 0.006) and fasting glucose levels (r = 0.59; p = 0.001).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796985     DOI: 10.1007/bf00410282

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

1.  Evidence that two naturally occurring human insulin receptor alpha-subunit variants are immunologically distinct.

Authors:  G Sesti; M A Marini; A Montemurro; L Condorelli; P Borboni; H U Haring; A Ullrich; I D Goldfine; R De Pirro; R Lauro
Journal:  Diabetes       Date:  1992-01       Impact factor: 9.461

2.  Structure of the human insulin receptor gene and characterization of its promoter.

Authors:  S Seino; M Seino; S Nishi; G I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Human insulin receptor radioimmunoassay: applicability to insulin-resistant states.

Authors:  V Pezzino; V Papa; V Trischitta; A Brunetti; P A Goodman; M K Treutelaar; J A Williams; B A Maddux; R Vigneri; I D Goldfine
Journal:  Am J Physiol       Date:  1989-09

4.  The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.

Authors:  Y Ebina; L Ellis; K Jarnagin; M Edery; L Graf; E Clauser; J H Ou; F Masiarz; Y W Kan; I D Goldfine
Journal:  Cell       Date:  1985-04       Impact factor: 41.582

5.  Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes.

Authors:  L Mosthaf; J Eriksson; H U Häring; L Groop; E Widen; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Peptide-based radioimmunoassay for insulin receptor. Detection of insulin-stimulated downregulation in IM-9 lymphocytes.

Authors:  K C McFarland; J Ramachandran; C Grunfeld
Journal:  Diabetes       Date:  1989-08       Impact factor: 9.461

7.  Regulation of human insulin receptor RNA splicing in HepG2 cells: effects of glucocorticoid and low glucose concentration.

Authors:  S Norgren; L S Li; H Luthman
Journal:  Biochem Biophys Res Commun       Date:  1994-02-28       Impact factor: 3.575

8.  Ligand-binding properties of the two isoforms of the human insulin receptor.

Authors:  Y Yamaguchi; J S Flier; H Benecke; B J Ransil; D E Moller
Journal:  Endocrinology       Date:  1993-03       Impact factor: 4.736

9.  Expression of insulin receptor spliced variants and their functional correlates in muscle from patients with non-insulin-dependent diabetes mellitus.

Authors:  T Hansen; C Bjørbaek; H Vestergaard; K Grønskov; J F Bak; O Pedersen
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  5 in total

1.  Delayed intracellular dissociation of the insulin-receptor complex impairs receptor recycling and insulin processing in cultured Epstein-Barr virus-transformed lymphocytes from insulin-resistant subjects.

Authors:  G Sesti; R D'Alfonso; M D Vargas Punti; A N Tullio; Y Y Liu; M Federici; P Borboni; M A Marini; R Lauro; A Fusco
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

2.  Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects.

Authors:  M Federici; L Zucaro; O Porzio; R Massoud; P Borboni; D Lauro; G Sesti
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

3.  Increased expression of low-affinity insulin receptor isoform and insulin/insulin-like growth factor-I hybrid receptors in term placenta from insulin-resistant women with gestational hypertension.

Authors:  H Valensise; Y Y Liu; M Federici; D Lauro; D Dell'anna; C Romanini; G Sesti
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

4.  Aberrant liver insulin receptor isoform a expression normalises with remission of type 2 diabetes after gastric bypass surgery.

Authors:  Vinko Besic; Hongjun Shi; Richard S Stubbs; Mark T Hayes
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

Review 5.  Alternative mRNA Splicing in the Pathogenesis of Obesity.

Authors:  Chi-Ming Wong; Lu Xu; Mabel Yin-Chun Yau
Journal:  Int J Mol Sci       Date:  2018-02-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.